Fundz

Elucid secures $55 million in an oversubscribed Series D financing led by a large medtech company. This round aims to enhance AI-powered technology for cardiovascular diagnosis and treatment.

PRIVATESep 02, 2026

Amount Raised

$55 Million

Round Type

Series D

BostonManufacturingHealth Care

Investors

Elevage Medical TechnologiesIAG Capital Partners

Description

Elucid, a medical technology company, has raised $55 million in an oversubscribed Series D financing. This round includes new participation from a significant medtech company, marking it as Elucid’s fourth publicly-traded strategic investor. The funds will further advance their AI-powered software for precision diagnosis and treatment of cardiovascular disease. The total funding raised by Elucid to date is approximately $185 million.

Who to call at Elucid, and when

A new round usually means Elucid is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Elucid raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Elucid, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Elucid

Location

Boston, Massachusetts, United States

About

Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid's CTA analysis equips physicians with critical information designed to enable precision medicine. Elucid is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. Elucid's unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Elucid raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Predictive Intelligence
Strategic

ML-powered predictions for Elucid's next move

See what Strategic adds

Elucid raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.